摘要
We are optimistic about Professor Shukui Qin and colleagues’electrifying results regarding the efficacy and safety of donafenib(a modified form of sorafenib)over sorafenib in treating advanced hepatocellular carcinoma(aHCC)(1).Following the landmark sorafenib trial in 2008(2),the present ZGDH3 trial is the first and only first-line head-to-head phase 2-3 trial to demonstrate that monotherapy is superior to sorafenib in terms of overall survival(OS)for aHCC.For the ZGDH3 trial,Qin et al.randomly assigned 668 eligible patients to receive 200 mg of donafenib or 400 mg of sorafenib,orally,twice daily,with open-label administration[donafenib(n=334),sorafenib(n=334)].The primary endpoint was OS and secondary endpoints included progression-free survival(PFS),time to progression,objective response rate(ORR),disease control rate(DCR),survival rates at 6,9,12,and 18 months,and safety.
基金
This work was funded by the National Natural Science Foundation of China(No.81770653 and 82070674)
the Clinical New Technology Project of West China Hospital,Sichuan University(No.20HXJS012)
the Sichuan Science and Technology Program(2019YFS0204).
